Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis

Fertility and Sterility

Volumn 94, Issue 2, 2010, Pages 558-563

  Chatzidarellis, Eleftherios ^a   Makrilia, Nektaria ^a   Giza, Laura ^b   Georgiadis, Efstratios ^b   Alamara, Christina ^a,b   Syrigos, Konstantinos N ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b TYPET Ygeias Melathron Hospital   (Greece)

Author keywords

Chemotherapy; docetaxel; gonadotoxicity; infertility; paclitaxel; taxanes

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; DOCETAXEL; FOLLITROPIN; GEMCITABINE; GONADOTROPIN; INHIBIN B; LUTEINIZING HORMONE; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FERTILITY; FOLLITROPIN BLOOD LEVEL; GONAD DYSFUNCTION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; LUTEINIZING HORMONE BLOOD LEVEL; MALE; PRIORITY JOURNAL; SPERMATOGENESIS; TESTIS SIZE;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARBOPLATIN; DEOXYCYTIDINE; FERTILITY; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY, MALE; INHIBINS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; SPERMATOGENESIS; TAXOIDS; TESTIS; YOUNG ADULT;

EID: 77953721557     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.03.068     Document Type: Article

References (29)

1. Rowinsky E., and Tolcher A. Pharmacology of cancer chemotherapy: antimicrotubule agents. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 7th ed (2005), Lippincott Williams & Wilkins, Philadelphia 390-416
2. Hensley M.L., Schuchter L.M., Lindley C., Meropol N.J., Cohen G.I., Broder G., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17 (1999) 3333-3355
3. National Cancer Institute Cancer Therapy Evaluation Program. Common terminology criteria for adverse events version 3.0. Available from: URL:http://ctep.info.nih.gov.
4. Lee S., Schover L., Partridge A., Patrizio P., Wallace W.H., Hagerty K., et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24 (2006) 2917-2931
5. Schover L.R., Brey K., Lichtin A., Lipshultz L.I., and Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 20 (2002) 1880-1889
6. Schover L.R., Rybicki L.A., Martin B.A., and Bringelsen K.A. Having children after cancer: a pilot survey of survivors' attitudes and experiences. Cancer 86 (1999) 697-709
7. Zebrack B.J., Casillas J., Nohr L., Adams H., and Zeltzer L.K. Fertility issues for young adult survivors of childhood cancer. Psychooncology 13 (2004) 689-699
8. Duffy C.M., Allen S.M., and Clark M.A. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 23 (2005) 766-773
9. Trottmann M., Becker A., Stadler T., Straub J., Soljanik I., Schlenker B., et al. Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation. Eur Urol 52 (2007) 355-367
10. Bolten M., Weissbach L., and Kaden R. [Cryopreserved human sperm deposits: usability after decades of storage.]. Urologe A 44 (2005) 904-908
11. Puscheck E., Philip P.A., and Jeyendran R.S. Male fertility preservation and cancer treatment. Cancer Treat Rev 30 (2004) 173-180
12. Colpi G.M., Contalbi G.F., and Nerva F. Testicular function following chemo-radiotherapy. Eur J Obstet & Gynecol Reprod Biol 113 Suppl 1 (2004) S2-S6
13. Takizawa S., and Horii I. Significant endocrinological parameters for the assessment of male reproductive toxicity induced by 1,3-dinitrobenzene or Taxol. J Toxicol Sci 26 (2001) 241
14. Lampe H., Horwich A., Norman A., Nicholls J., and Dearnaley D.P. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15 (1997) 239-245
15. US Food and Drug Administration. CDER human drugs. Available from: URL:http://www.fda.gov/cder/index.html.
16. Meistrich M.L., Vassilopoulou-Sellin R., and Lipshultz L.I. Adverse effects of treatment: gonadal dysfunction. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 7th ed (2005), Lippincott Williams & Wilkins, Philadelphia 2560-2574
17. Schlegel P., and Hardy M. Male reproductive physiology. In: Walsh P., Retik A., Vaughan E., and Wein A. (Eds). Campbell's urology. 8th ed (2002), Saunders, Philadelphia 3745-3788
18. Daniel Jr. W.A., Feinstein R.A., Howard-Peebles P., and Baxley W.D. Testicular volumes of adolescents. J Pediatr 101 (1982) 1010-1012
19. Lambert B. The frequency of mumps and of mumps orchitis and the consequences for sexuality and fertility. Acta Genet Stat Med 2 Suppl 1 (1951) 1-166
20. Taskinen S., Taavitsainen M., and Wikstrom S. Measurement of testicular volume: comparison of 3 different methods. J Urol 155 (1996) 930-933
21. Lahteenmaki P., Toppari J., Ruokonen A., Laitinen P., and Salmi T.T. Low serum inhibin B concentrations in male survivors of childhood malignancy. Eur J Cancer 35 (1999) 612-619
22. Groome N.P., and Evans L.W. Does measurement of inhibin have a clinical role?. Ann Clin Biochem 37 Pt 4 (2000) 419-431
23. Andersson A.M. Inhibin B in the assessment of seminiferous tubular function. Baillieres Best Pract Res Clin Endocrinol Metab 14 (2000) 389-397
24. Anawalt B.D., Bebb R.A., Matsumoto A.M., Groome N.P., Illingworth P.J., McNeilly A.S., et al. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 81 (1996) 3341-3345
25. Klingmuller D., and Haidl G. Inhibin B in men with normal and disturbed spermatogenesis. Hum Reprod 12 (1997) 2376-2378
26. Andersson A.M., Petersen J., Jorgensen N., Jensen T.K., and Skakkebaek N.E. Serum inhibin B and follicle-stimulating hormone levels as tools in the evaluation of infertile men: significance of adequate reference values from proven fertile men. J Clin Endocrinol Metab 89 (2004) 2873-2879
27. Von Eckardstein S., Simoni M., Bergmann M., Weinbauer G.F., Gassner P., Schepers A.G., et al. Serum inhibin B in combination with serum follicle-stimulating hormone (FSH) is a more sensitive marker than serum FSH alone for impaired spermatogenesis in men, but cannot predict the presence of sperm in testicular tissue samples. J Clin Endocrinol Metab 84 (1999) 2496-2501
28. Pierik F.H., Vreeburg J.T., Stijnen T., De Jong F.H., and Weber R.F. Serum inhibin B as a marker of spermatogenesis. J Clin Endocrinol Metab 83 (1998) 3110-3114
29. Reh A., Oktem O., and Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 90 (2008) 1635-1639